Illinois Municipal Retirement Fund Purchases 1,524 Shares of Medpace Holdings, Inc. $MEDP

Illinois Municipal Retirement Fund boosted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 63.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,932 shares of the company’s stock after buying an additional 1,524 shares during the period. Illinois Municipal Retirement Fund’s holdings in Medpace were worth $1,888,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of MEDP. State of Michigan Retirement System boosted its position in shares of Medpace by 1.9% during the 1st quarter. State of Michigan Retirement System now owns 5,399 shares of the company’s stock valued at $2,593,000 after acquiring an additional 100 shares in the last quarter. Principal Financial Group Inc. raised its position in Medpace by 5.7% in the first quarter. Principal Financial Group Inc. now owns 50,442 shares of the company’s stock worth $24,222,000 after purchasing an additional 2,740 shares in the last quarter. Chicago Partners Investment Group LLC raised its position in Medpace by 10.0% in the first quarter. Chicago Partners Investment Group LLC now owns 2,109 shares of the company’s stock worth $1,072,000 after purchasing an additional 191 shares in the last quarter. Diversify Wealth Management LLC lifted its stake in Medpace by 93.2% during the first quarter. Diversify Wealth Management LLC now owns 6,429 shares of the company’s stock worth $3,087,000 after purchasing an additional 3,101 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in Medpace by 0.9% during the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 5,618 shares of the company’s stock worth $2,698,000 after purchasing an additional 49 shares during the period. Institutional investors own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

MEDP has been the topic of several analyst reports. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and upped their price objective for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. Wall Street Zen downgraded Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Medpace in a research note on Thursday, July 2nd. Barclays lowered their price target on Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research report on Friday, April 24th. Finally, Robert W. Baird reiterated a “neutral” rating and set a $547.00 price objective (up from $477.00) on shares of Medpace in a research note on Wednesday, July 8th. Two investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $469.50.

Medpace Stock Performance

Shares of MEDP opened at $527.93 on Tuesday. The company has a market cap of $15.08 billion, a price-to-earnings ratio of 33.18, a PEG ratio of 2.69 and a beta of 1.15. The stock has a fifty day moving average price of $480.31 and a two-hundred day moving average price of $493.94. Medpace Holdings, Inc. has a 52-week low of $306.70 and a 52-week high of $628.92.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. The company had revenue of $706.60 million during the quarter, compared to analyst estimates of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The firm’s quarterly revenue was up 26.5% compared to the same quarter last year. During the same period last year, the company posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, research analysts predict that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Insider Activity

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares in the company, valued at approximately $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 20.50% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.